GlassScriptPhysician profile
Christopher W Sorrels
NPI 1023085636
$3,134.50
in general payments reported to CMS, 2019-2025
21 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $169 · 2021: $124 · 2022: $570 · 2023: $378 · 2024: $609 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $743.96 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $634.35 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $592.09 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $328.51 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $219.74 | 2022-2025 | Vraylar, Lo Loestrin Fe |
| Supernus Pharmaceuticals, INC. | $86.71 | 2022 | |
| Janssen Pharmaceuticals, INC | $69.22 | 2022-2023 | Xarelto |
| Exact Sciences Corporation | $68.91 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $64.35 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $55.01 | 2024-2025 | Uzedy |
| Corium, LLC | $46.75 | 2023 | Azstarys |
| Biogen, INC. | $45.20 | 2025 | Skyclarys |
| Mylan Specialty L.P. | $40.21 | 2024 | Yupelri |
| Astellas Pharma US INC | $23.58 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $22.54 | 2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $18.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.19 | 2022 | |
| Glaxosmithkline, LLC. | $16.81 | 2024 | Trelegy Ellipta |
| Allergan, INC. | $14.39 | 2020 | |
| Dexcom, INC. | $13.87 | 2023 | Dexcom G6 Transmitter |
| Amgen INC. | $12.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Sorrels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.